Nesfatin-1 decreases the motivational and rewarding value of food.

Riccardo Dore, Regina Krotenko, Jan Philipp Reising, Luca Murru, Sivaraj Mohana Sundaram, Alessandro Di Spiezio, Helge Müller-Fielitz, Markus Schwaninger, Olaf Jöhren, Jens Mittag, Maria Passafaro, Marya Shanabrough, Tamas L Horvath, Carla Schulz, Hendrik Lehnert

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2021;45(10):1645-1655

PMID: 32353862

Abstract

Homeostatic and hedonic pathways distinctly interact to control food intake. Dysregulations of circuitries controlling hedonic feeding may disrupt homeostatic mechanisms and lead to eating disorders. The anorexigenic peptides nucleobindin-2 (NUCB2)/nesfatin-1 may be involved in the interaction of these pathways. The endogenous levels of this peptide are regulated by the feeding state, with reduced levels following fasting and normalized by refeeding. The fasting state is associated with biochemical and behavioral adaptations ultimately leading to enhanced sensitization of reward circuitries towards food reward. Although NUCB2/nesfatin-1 is expressed in reward-related brain areas, its role in regulating motivation and preference for nutrients has not yet been investigated. We here report that both dopamine and GABA neurons express NUCB2/nesfatin-1 in the VTA. Ex vivo electrophysiological recordings show that nesfatin-1 hyperpolarizes dopamine, but not GABA, neurons of the VTA by inducing an outward potassium current. In vivo, central administration of nesfatin-1 reduces motivation for food reward in a high-effort condition, sucrose intake and preference. We next adopted a 2-bottle choice procedure, whereby the reward value of sucrose was compared with that of a reference stimulus (sucralose + optogenetic stimulation of VTA dopamine neurons) and found that nesfatin-1 fully abolishes the fasting-induced increase in the reward value of sucrose. These findings indicate that nesfatin-1 reduces energy intake by negatively modulating dopaminergic neuron activity and, in turn, hedonic aspects of food intake. Since nesfatin-1´s actions are preserved in conditions of leptin resistance, the present findings render the NUCB2/nesfatin-1 system an appealing target for the development of novel therapeutical treatments towards obesity.

Address: Department of Internal Medicine I, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. [email protected].; Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. [email protected].; Department of Internal Medicine I, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.; Center of Brain, Behavior and Metabolism (CBBM), University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.; Department of Women's and Children's Health, Karolinska Institutet, 171 76, Stockholm, Sweden.; CNR, Institute of Neuroscience, 20129, Milan, Italy.; Institute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.; Department of Biochemistry, University of Kiel, 24118, Kiel, Germany.; Department of Comparative Medicine, Program on Integrative Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT, 06520, USA.; Department of Anatomy and Histology, University of Veterinary Medicine, Budapest, H-1078, Hungary.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.